Five things for pharma marketers to know: Monday, March 26, 2018

Share this content:


Ablynx, Sanofi's biotech firm, is dropping vobarilizumab after the drug failed to meet its primary endpoints in a Phase II lupus study. Ablynx licensed the drug from Abbvie in 2013. Abbvie cut vobarilizumab in 2016 following a failed rheumatoid arthritis study. (Endpoints)

 

In a Phase III study, Biohaven's migraine drug met its primary endpoints of freedom from pain and bothersome symptoms, but the company's stock still tumbled, as investors weren't convinced by the strength of the results. Shares of Allergen, which is developing a rival migraine drug, were up slightly. (Xconomy)

 

The White House's strategy for fighting the opioid crisis includes using a single drug, naltrexone, manufactured by Vivitrol, for treating addicted inmates in the federal criminal justice system. The drug blocks the effects of opioids and reduces cravings, but addiction experts say multiple-medication-assisted treatments should be available according to patient need. (STAT)

 

Roche's Tecentriq immunotherapy, when combined with other drugs, improved lung cancer patients' survival in a trial. In a separate study published last week, Tecentriq was found to boost progression-free survival in patients with advanced squamous non-small-cell lung cancer when mixed with chemotherapies carboplatin and Abraxane, compared with chemotherapy alone. (Reuters)

 

The FDA wants to regulate medicines produced in bulk by compounding pharmacies that have not been approved by the agency. It issued draft guidance that prioritizes the use of FDA-approved drugs over custom-made medicines. (Reuters)

Share this content:
Scroll down to see the next article